Our collaborators 2016-2017
We collaborate widely with health professionals, academics and industry both in Australia and abroad. This table shows our collaborators in 2016-2017:
|
Institution |
Research area and Project |
Collaborator(s) |
|---|---|---|
|
Australian National University |
Product safety: Novel red cell targets for biopharmaceuticals. |
Prof. Simon Foote, Dr Brendan McMorran, Dr Gaétan Burgio |
|
James Cook University |
Product safety: Exotic mosquito-borne virus threats to Australia (including WNV, CHIKV, LNV etc.): disease burden and consequences for blood supply safety |
Prof. John McBride |
|
Monash University |
Product usage: Transfusion Outcomes Research Collabrative (TORC). |
Prof. J Mc Neill and members of the TORC Steering committee |
|
Murdoch University |
Product safety: Red cell storage duration and procoagulant effects: Role of microparticles and smaller particles. |
Ross Baker and Quentin Hughes |
|
Queensland University of Technology |
Product safety: Red cell alloimmunisation: How can extended genotyping support the ongoing transfusion needs of haemoglobinopathy patients? |
Prof. Louise Hafner |
|
|
Product safety: reducing the risk of TRALI. |
Prof. Adrian Barnett, Anne-Marie Christensen |
|
|
Donor behaviour: Hospitals to Hospitality: Understanding the influence of Interaction with staff and service quality on donor intention to donate. |
Prof. Rebekah Russell-Bennett |
|
|
Product safety: Points of structural failure that may lead to storage-related changes of red cells. |
Prof YT Gu, Dr E Sauret, Dr S Saha and Prof Y Xiao, Sarah Barns, Dr Alex Stilgoe |
|
|
Product safety: What is the risk of alloimmunisation by transfusion of variant RhD red blood cells that serotype as RhD Negative? |
Christine Knauth |
|
|
Product safety: Is parvovirus B19 a concern for the blood safety in Australia? |
Dr Francesca Frentiu |
|
|
Product safety: Red cell storage duration and procoagulant effects: Role of microparticles and smaller particles. |
Dr Natalie Pecheniuk |
|
University of Newcastle |
Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety? |
Prof. Stephen Graves |
|
University of NSW |
Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety? |
Dr Heather Gidding |
|
|
Donor behaviour: Emotional Psychology of Blood Donors. |
Dr Lisa Williams |
|
|
Product develoment and storage: Biomimetic blood bag materials for prolonged platelet storage. |
Prof. John Whitelock, Dr Megan Lord, Dr Brooke Farrugia |
|
University of Queensland |
Product safety: Reducing the risk of TRALI. |
Prof. Michael Reade |
|
|
Donor Behaviour: multiple projects. |
A/Prof. Barbara Masser (co-appointment) |
|
|
Product safety: Inactivation of Zika virus in plasma and in platelet concentrates following treatment with the THERAFLEX pathogen inactivation (PI) technologies. |
Prof Roy Hall, Dr Jody Hobson Peters, Dr Daniel Watterson, Prof Paul Young |
|
|
Product safety: Exotic mosquito-borne virus threats to Australia (including WNV, CHIKV, LNV etc.):disease burden and consequences for blood supply safety. |
Prof. John Aaskov, Prof. Roy Hall (UQ), Dr Helle Bielefeldt-Ohman, Dr John Wright, Dr Jasimme Uddin |
|
|
Donor behaviour: Hospitals to Hospitality: Understanding the influence of Interaction with staff and service quality on donor intention to donate. |
Dr Josephine Peevite |
|
|
Product safety: Novel red cell targets for biopharmaceuticals. |
Dr Benjamin Shultz |
|
University of South Australia |
Product safety: Chikungunya and/or Zika virus emergence and establishment in Australia. |
A/Prof Craig Williams, Gina Mincham |
|
University of Sydney |
Donor Behaviour: Behavioural economics to understand blood donations. |
Evarn Ooi co-appointment with Prof. Robert Slonim |
|
|
Centre for Values, Ethics and the Law in Medicine: APPRISE partner. |
Prof. Angus Dawson |
|
|
Product development and storage: Development and characterisation of platelet lysate. |
Dr Zufu Lu |
|
University of Technology Sydney |
Donor health and wellbeing: biostatistics, several projects. |
Louise Ryan |
|
|
Product development and storage: Characterisation of cryopreserved platelets. Product development and storage: Cold storage of platelets. |
Dr Matthew Padula |
|
Research area and Project |
Collaborator(s) |
|
|---|---|---|
|
Hospitals |
||
|
Canberra Hospital |
Product safety: Investigating levels of BRMs in donors implicated in clinical cases of TRALI. |
Prof. Matthew Cook, Dr Zuopeng Wu |
|
Concord Repatriation and General Hospital |
Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? |
Prof Peter Maitz , Dr Rosalba Cross |
|
Flinders Medical Centre |
The incidence of microchimerism in chronically transfused patients. |
A/Prof. David Roxby |
|
Gosford Hospital |
Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? |
Dr Duncan Reed |
|
John Hunter Hospital |
Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? |
Prof. Zsolt Balogh |
|
Mater Mothers’ Hospital Brisbane |
Product usage: The incidence of microchimerism in paediatric patients. |
Dr Bryony Ross |
|
|
Product safety: Reduction in anti-D immunoglobulin usage by genotyping: a cost (and) benefit analysis. |
Dr Glen Gardener |
|
Orange Health Service |
Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? |
Dr Doug Lenton, A/Prof Brian Burns |
|
Prince Charles Hospital |
Product safety: Reducing the risk of TRALI and Reducing the risks associated with transfusion. |
Prof John Fraser and the Prince Charles Hospital Critical Care Research Group |
|
|
Product safety: Transfusion associated immunomodulation in a cohort of cardiac patients – translating laboratory findings to a clinical context. |
Dr Rishendran Naidoo and Prof John Fraser |
|
Prince of Wales Hospital |
Product usage: An open label, single arm clinical trial assessing the safety and efficacy of allogeneic 20% serum eye drops in severe dry eye patients. |
Prof Minas Coroneo |
|
Royal Melbourne Hospital |
Product usage: The incidence of microchimerism in chronically transfused patients. |
Dr Chris Ward, Dr Lesley Survela |
|
Royal North Shore Hospital |
Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? |
Dr Tony Joseph, Dr Mark Gillett, Dr Lesley Survela |
|
|
Product safety: Red cell alloimmunisation: How can extended genotyping support the ongoing transfusion needs of haemoglobinopathy patients? |
Prof Chris Ward |
|
|
Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting. |
Prof James Isbister, Dr Jennifer |
|
Royal Perth Hospital |
Product development and storage: Development and characterisation of platelet lysates. |
Dr Marian Sturm and Dr Leon Brownrigg |
|
|
Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing |
A/Prof. Timothy Day, Prof. Lynettte Kiers |
|
Royal Prince Alfred Hospital |
Product safety: Reduction in anti-D immunoglobulin usage by genotyping: a cost (and) benefit analysis. |
Clin Prof. Jonathon Hyett |
|
|
Product Safety: Non-invasive assessment (NIPA) translation: for high risk pregnant women who are allo-immunised to the RhD blood group antigen. |
Clin Prof. Jonathon Hyett |
|
|
Product development and storage: Development and characterisation of platelet lysate. |
Dr Janet McPherson and Dr James Favaloro |
|
St George Hospital |
Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? |
Dr Mary Langcake |
|
Sydney Eye Hospital |
Product development and storage: Development and characterisation of platelet lysate. |
Simon Cooper |
|
Westmead Hospital |
Product usage: Blood product safety in massive transfusion recipients - Does white cell filtration really remove transfusion risk? |
Dr Jeremy Hsu, Dr Leonardo Pasalic |
|
Research area and Project |
Collaborator(s) |
|
|---|---|---|
|
Government Health Departments and Agencies |
||
|
Clinical Excellence Commission, NSW |
Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting. |
Dr Amanda Thomson |
|
Hunter New England Health |
Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety? |
Prod. David Durrheim |
|
National Centre for Immunisation research and surveillance |
Product safety: Q Fever: how common is it, who is at risk and what does this mean for blood safety? |
Dr NIck Wood, Dr Helen Quinn, Prof. Peter McIntyre |
|
National Blood Transfusion Committee |
To review the use of O negative red cells, cryoprecipitate and washed cells nationally |
|
|
NSW Office of Kids and Families |
Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting. |
Associate Professor Michael Nicholl |
|
Queensland Health |
Product safety: Q fever: how common is it, who is at risk and what does this mean for blood safety? |
Dr Penny Hutchison |
|
|
Product safety: Transfusion Transmitted Infections and Emerging Risks - Chikungunya and/or Zika virus emergence and establishment in Australia. |
Cassie Jansen, Brian Montgomery |
|
SA Pathology |
Product safety: Red cell alloimmunisation: How can extended genotyping support the ongoing transfusion needs of haemoglobinopathy patients? |
A/Prof. David Roxby |
|
Research area and Project |
Collaborator(s) |
|
|---|---|---|
|
Research Institutes |
||
|
ARC Centre of Excellence for Mathematical & Statistical Frontiers (ACEMS) |
Donor Health and Wellbeing: 45 and Up: Lifeblood data linkage project: a world-class donor health data-asset. |
Prof. Louise Ryan |
|
Australian Genome Research Facility |
Product safety: Genetic basis for blood groups. |
|
|
Centre for Biopharmaceutical Innovation |
Product safety: Novel red blood cell targets for biopharmaceuticals. |
Professor Steven Mahler, Dr Xuan Bui |
|
Centre for Children’s Health Research |
Product safety: Is parvovirus B19 a concern for blood safety in Australia? |
Dr Sarah Tozer, Seweryn Bialasiewicz |
|
Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead |
Product safety: APPRISE partner. |
Prof Lyn Gilbert |
|
Mater Medical Research Institute |
Product Safety: Non-invasive assessment (NIPA) translation: for high risk pregnant women who are allo-immunised to the RhD blood group antigen. |
Dr Glenn Gardener, Anne Tremellen |
|
National Centre for Immunisation Research and Surveillance |
Product safety: Q fever: how common is it, who is at risk and what does this mean for blood safety? |
Dr Nick Wood, Dr Helen Quinn, Prof. Peter McIntyre |
|
Perth Blood Institute |
Product safety:red cell storage duration and procoagulant effects: Role of microparticles and smaller particles |
Ross Baker and Quentin Hughes |
|
Queensland Institute of Medical Research-Berghofer Medical research institute |
Product safety: Detection of Ross River virus in Australian blood donations. |
Dr Natalie Prow |
|
|
Product safety: Exotic mosquito-borne virus threats to Australia (including WNV, |
Prof Andreas Suhrbier, Dr Greg Devine |
|
|
Product safety: Reduction in anti-D immunoglobulin usage by genotyping: a cost (and) benefit analysis. |
Dr Louisa Gordon |
|
Save Sight Institute |
Product usage: An open label, single arm clinical trial assessing the safety and efficacy of allogeneic 20% serum eye drops in severe dry eye patients |
Dr Con Petsoglou |
|
Sax Institute |
Donor Health and Wellbeing: 45 and up study: Lifeblood data linkage project: a world-class donor health data-asset. |
|
|
The Australian and New Zealand Intensive Care Research Centre |
Product usage: TRANSFUSE - Standard Issue Transfusion versus fresher red blood cell use in intensive care - a randomised controlled trial. |
Prof DJ (Jamie) Cooper |
|
The Kolling Institute, University of Sydney |
Product usage: Exploring the impact of blood transfusion on maternity outcomes and healthcare utilisation: informing the use of blood and blood products in the obstetric setting |
A/Prof Jane Ford, Prof Jonathan Morris, Ms Jillian Patterson |
|
Vision Eye Institute |
Product usage: An open label, single arm clinical trial assessing the safety and efficacy of allogeneic 20% serum eye drops in severe dry eye patients. |
Dr Colin Chan |
|
Research area and Project |
Collaborator(s) |
|
|---|---|---|
|
Industry |
||
|
Australian Defence Force |
Product usage: Clip Trial - Cryopreserved versus Liquid Stored Platelets for surgical bleeding. |
Prof. Michael Reade |
|
Blood Systems Research Institute |
Product safety: Exotic mosquito-borne virus threats to Australia (including WNV, CHIKV, LNV etc.):disease burden and consequences for blood supply safety |
Prof. Eric Delwart |
|
CSL |
Product usage:Validation of candidate immune biomarkers as predictors of IVIg response in CIDP patients to promote cost-effective IVIg dosing. |
Dr Souravi Ghosh, Dr Adrian Zuercher and Dr Bradley Sedgmen |
|
Grifols |
Product safety: Does hepatitis E virus pose a risk to the Australian blood supply? |
Dr Jerry Holmberg |
|
Macopharma |
Product usage: A Phase III prospective, randomised, double-blinded multicentre clinical trial on clinical efficacy and safety of platelet concentrates treated with the Theraflex UV-Platelets system in comparison to conventional platelet components. |
|
|
|
Product safety: Inactivation of Zika virus in plasma and in platelet concentrates following treatment with the THERAFLEX pathogen inactivation (PI) technologies |
Dr Stefan Reichenberg, Dr Frank Tolksdorf, Dr Chryslain Sumian |
|
New Health Sciences Inc |
Product development and storage: Anaerobic Red Cell storage. |
Dr Tatsuro Yoshida |
|
Research area and Project |
Collaborator(s) |
|
|---|---|---|
|
International |
||
|
Alberta Health Service Canada |
Product safety: What is the risk of alloimmunisation by transfusion of variant RhD red blood cells that serotype as RhD Negative? |
|
|
American Red Cross |
Product safety: Does hepatitis E virus pose a risk to the Australian blood supply? |
Dr Susan Stramer |
|
Canadian Lifeblood |
Product development and storage: Characterisation of cryopreserved platelets. |
Dr Peter Schubert, Dr Dana Devine |
|
|
Product development and storage: Use of additive solutions for reconstitution of platelets. |
Dr Jason Acker |
|
Dartmouth Hitchcock USA |
Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. |
Dr Larry Dumont |
|
Environmental Protection Authority, New Zealand |
Product safety: What is the risk of alloimmunisation by transfusion of variant RhD red blood cells that serotype as RhD Negative? |
Dr Stacy Scott |
|
Fiji National Lifeblood of the Republic of Fiji Islands Ministry of Health |
Product safety: Building Capacity to solve complex red cell serology using genetic sequencing. |
Adriu Sepeti |
|
German Red Cross Lifeblood, NTSOB |
Product safety: Inactivation of Zika virus in plasma and in platelet concentrates following treatment with the THERAFLEX pathogen inactivation (PI) technologies |
Dr Ute Gravemann, Dr Axel Seltsam |
|
McMaster University, Canada |
Product usage: A Phase III prospective, randomised, double-blinded multicentre clinical trial on clinical efficacy and safety of platelet concentrates treated with the Theraflex UV-Platelets system in comparison to conventional platelet components. |
Nancy Heddle |
|
Netherlands Military Blood Bank |
Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. |
Dr Femke Noorman |
|
New Zealand Lifeblood |
Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. |
Dr Darryl Crimmins |
|
Sanquin |
Donor health and wellbeing: Development of an Australian statistical model to predict haemoglobin deferrals. |
Dr Mireille Baart |
|
Singapore Defence Medical & Environmental Research Institute |
Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. |
Dr Jia Lu |
|
Scottish Blood Transfusion Service |
Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. |
Dr Juraj Petrik |
|
University of British Columbia |
Product development and storage: Pilot study to determine whether in vitro testing can identify the best donors for our platelet components. |
Dr Elisabeth Maurer |
|
University of Ohio |
Donor behaviour: Pilot trial of an innovative online intervention with first time O negative donors. |
Prof Chris France |
|
University of Ottawa |
Product development and storage: Use of additive solutions for reconstitution of cryopreserved platelets. |
Prof Robert Ben |